Telik Reports Prelim. Deal on Design of Phase 3 Trial of Telintra in Low to Intermediate Risk Myelodysplastic Syndrome
Posted on January 22, 2013 at 17:31 PM EST
Telik, Inc. (Nasdaq: TELK ) announced the completion of an End of Phase 2 meeting with the US Food and Drug Administration (FDA). Preliminary agreement was reached regarding the design of a Phase 3 placebo-controlled randomized registration trial of Telintra (ezatiostat) for the treatment of Low to Intermediate-1 risk myelodysplastic syndrome (MDS), using red-blood-cell